pure ep™ system...sources: 1. electrophysiology devices market - global industry analysis, size,...

Symbol: BSGM

PURE EP™ System

Symbol: BSGM © 2016 BioSig Technologies, Inc. All rights reserved. The contents of this document are proprietary and confidential.

Disclaimer

This presentation contains forward-looking statements including statements that address activities, events or developmentsthat BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance,approvals and launches by BioSig of new products, market acceptance of BioSig’s products, market and procedureprojections, financing plans, and related documents. Forward-looking statements are based on BioSig’s experience andperception of current conditions, trends, expected future developments and other factors it believes are appropriate underthe circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig’s control.

These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance ofproducts, BioSig’s ability to develop and market new and enhanced products, the timing of and ability to obtain andmaintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances andapprovals on its ability to promote its products and train doctors in the use of its products, the timing of and ability toobtain reimbursement if required of procedures utilizing BioSig’s products and the potential impact of current healthcarereform initiatives thereon, competition from existing and new products and procedures or BioSig’s ability to effectively reactto other risks and uncertainties described from time to time in BioSig’s SEC filings, such as fluctuation of financial results,reliance on third party manufacturers and suppliers, litigation or other proceedings (including by the FDA), governmentregulation, negative publicity, current worldwide economic conditions and share price volatility.

BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected.Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result ofnew information, future events or otherwise.

1


Arrhythmias (Irregular Heartbeats) 1 in 18 (14.4M) Americans Suffer

2

ATRIAL FIBRILLATION (AF)Rapid/irregular heart rate that

commonly causes poor blood flow

US = 3.4M 2012 8-12M by 2050

1 In 4 Adults ≥ 65

↑ risk of Stroke 4- to 5-fold(5th Leading Cause of Death in US)

Total Direct/Indirect Costs $26B/yr

BioSig’s Goal: Better Outcomes for Patients with Complex Arrhythmias

VENTRICULAR TACHYCARDIA (VT)Rapid/irregular heartbeat inlower chambers of the heart

Ventricular tachycardia (VT) and ventricular fibrillation (VF) are rapidly fatal if not reversed

Accounts for >350,000/yr Sudden Cardiac Deaths in the US

American Heart Association data


Diagnosing Arrhythmias

3

BioSig offers improved clarity of acquired cardiac data even at the very low, until now, undetectable signal levels for better clinical decisions and diagnostics/outcomes

PURE EP System is different from current recording systems: its proprietary hardware and signal processing provides enhanced real-time information

Current Way

PURE EP: The High Fidelity Solution


Solving the EP Problem: PURE EP™ System

4

Information Unobtainable From Any Other EP Device Today

Proprietary Hardware / Signal Processing Capabilities / Ability to Open Multiple Review Windows

To Assist in Clinical Decision Making in Real-Time

To Maximize Ablation Efficacy & Minimize Need for Repeat Procedures

To Shorten & Simplify EP Procedures


Large & Fast Growing MarketAblation becoming First Line of Therapy

5

EP Labs: Estimated 4,000 WW; 2,800 in the US In 2014: Over 260,000 US total catheter ablation procedures; greater than 600,000 WW Average ablation procedure price (USD): $15,000

EP Devices: 12.1% CAGR is One of the Fastest Growing Medical Device Segments1

$2.5

$5.5

$- $1.0 $2.0 $3.0 $4.0 $5.0 $6.0

2012 2019

Sources: 1. Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019 2. HRI 2013 “Global Opportunities in Medical Devices & Diagnostics” report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter

Current EP Market is <$4 B worldwide

$ in

Bill

ions

U.S. AF & VT Complex CatheterAblation Procedures2

97,250

160,000

-

50,000

100,000

150,000

200,000

2012 2017

Forecasted to grow 10.5% annually through 2017


EP Recorder Competitive Landscape$750 MILLION - $1 BILLION Global Market

6

CardioLab50%

Lab Systems Pro15%

EP Workmate35%

Installed Global Unit Market Share


Shortcomings of Existing Treatments

7

Electrophysiology (EP) procedures: Catheters are advanced through a patient’s vessels and

placed on cardiac tissue to record intracardiac electrogram signals for diagnostic EP studies

During ablation treatments, RF energy is applied to cardiac tissue to destroy abnormal electrical pathways

DRUG THERAPIES OFTEN INEFFECTIVE

TECHNOLOGY FOR ABLATION TREATMENTS NEED IMPROVEMENT Predominantly anatomical markers Insufficient information and signal quality from

existing recording systems

LONG ABLATION PROCEDURE TIMES 2-8 hours depending on complexity, clinician experience

HIGH RATES OF RECURRING ARRHYTHMIAS Many undergo multiple procedures


Proven Management Team

8

Kenneth L. Londoner, MBA

Founder, Executive Chairman, Director; Endicott Management Partners, LLC, J & W Seligman & Co

Gregory D. CashPresident, CEO and Director; Pres: Argent International, NeuroTherm, HeartsineTech, Vasomedical, Datascope, Eminent Tech; Mgmt: U.S. Surgical, Boston Scientific, Medtronic

Steve Chaussy, CPA CFO; Liberski Inc, Anna & Co, Penske Automotive, Ford Hogg and Cobbe

Jay O. Millerhagen, MS, MBA

VP Clinical Research; VP Clinical/Mkt Dev: RESPICARDIA, Inc.; VP/Sr Dir Clinical: St Jude Medical; Dir New Product Planning, Brady Mktg, Heart Failure R&D/Mktg, Bus Alliance Mktg with J&J, GE Healthcare: Boston Scientific

Brian McLaughlin VP Corporate Finance, Investor Relations; President & COO: Ridgeback Capital;Head of Equity Trading: Sigma Capital; Trader: SAC Capital & JP Morgan & Co.

Asher Holzer, PhD. Chief Scientific Officer; Director/Pres/Chairman, InspireMD, Inc., Co-founder/Pres/Chairman, InspireMD Ltd., Founder/CEO, Adar Medical Ltd.


Board of Directors

9

Kenneth L. Londoner, MBA Founder, Executive Chairman, Director; Endicott Management Partners, J & W Seligman & Co

Gregory D. Cash President, CEO and Director: U.S. Surgical, Boston Scientific, Medtronic

Roy T. Tanaka Director; Former CEO of BioSense Webster, Johnson & Johnson; Volcano Corp, VytronUS, Coherex Medical

Seth H. Z. Fischer Director; Current CEO & Dir: Vivus, Inc; Former WW Chairman: Johnson & Johnson, Cardiovascular

Patrick J. Gallagher, MBA Director; Managing Director Laidlaw & Co.; Kinex Pharma; Founder BDR Research Group, Kidder Peabody

Jeffrey F. O’Donnell, Sr. Director; CEO, Chair: Trice Medical; Chair: Mela Sciences; Founder: Embrella Cardiovascular

Jerome B. Zeldis, MD, PhD Director; CEO of Celgene Global Health & Chief Medical Officer of Celgene Corporation; Chairman: Alliqua

David Weild IV, MBA Director; Founder & CEO: Weild & Co.; Vice Chairman: NASDAQ; Head of Corporate Finance Prudential

Donald E. Foley Director; CEO & Chair: Wilmington Trust; Sr VP, Treas, & Dir: ITT Corp; Asst Treas: Int’l Paper Co.


World-Class Scientific Advisory Board Top authorities in electrophysiology

10

Andrea Natale, MD, Chairman Executive Medical Director, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center

Samuel Asirvatham, MD Professor of Medicine & Vice Chair of Division of Cardiovascular Diseases, Department of Medicine; program director Clinical Cardiac Electrophysiology Training Program, Mayo Clinic in Rochester, Minnesota

K. L. Venkatachalam, MD Assistant Professor of Medicine, Division of Cardiovascular Diseases, Mayo Clinic in Jacksonville, Florida

Kalyanam Shivkumar, MD, PhD Director, UCLA Cardiac Arrhythmia Center; Professor of Medicine & Radiology

Mauricio Arruda, MD Director, Clinical Electrophysiology & Pacing, University Hospitals Case Medical Center

Vivek Reddy, MD Director, Cardiac Arrhythmia Service and a Helmsley Trust Professor of Medicine, Mount Sinai Medical Center in New York

Luigi Di Biase, MD, PhD Senior Researcher at Texas Cardiac Arrhythmia Institute; Associate Professor, Albert Einstein College of Medicine, Adjunct Professor at the UT Austin


PURE EP – Novel Information System Collaborating with Leading Centers

11

June 2011

Concept Developed with Texas Cardiac

Arrhythmia Institute

June 2013

PURE EP System Proof of Concept

(POC) Test at UCLA

September 2014

PURE EP System Prototype Test at

UCLA

December 2014

Visit to Mayo Clinic to plan Pre-

Clinical Studies

March, June &November 2015

Pre-Clinical Studies at Mayo

Clinic

October 2015

Pre-Clinical Studies at UCLA

Other Collaborations

William Beaumont Hospital in MichiganUH Case Medical

Center in Cleveland

Mount SinaiMedical Center


PURE EP: A Few Key Advantagesas stated by Dr. Samuel Asirvatham, Mayo Clinic

12

MDDI - http://www.mddionline.com/article/cutting-out-noise-target-arrhythmias-07-08-15

"The dynamic range of the system is larger - likely will translate into better

ability to see both large and small (frequency and amplitude) signals

with similar resolution. This is a major problem with present systems, where in order to see smaller signals, we have to amplify the signals, and in

doing so, we lose the ability to see larger signals without saturating

these signals.”

“The improved resolution may translate to better

ability to pick up specific signals and relate them to specific structure and

substrate.”

"The display options are also more intuitive and flexible. For

example, different filtering can be applied to the same signal and

displayed as separate, simultaneous signals. Presently

this is not possible with the existing systems to my

knowledge."

http://www.mddionline.com/article/cutting-out-noise-target-arrhythmias-07-08-15


PURE EPTM System: Path to Market

Sales & Marketing in US Requires a 510(k) Clearance

PURE EPTM System Qualifies as a Class II Device

Extensive Clinical Work is Not Required

Estimated Time for Clearance is Late 2016

13


PURE EPTM System: Path to Market

14

2016 2017Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

Phase 1Design Requirements

Design Plan Risk Reduction

Phase 2Detailed Design

Engineering Confidence Testing

& Alpha Build

Phase 3Design

Refinements Beta Design

Phase 4Beta Build

Verification Testing Pre-production

activities

FDA Review

Launch Prep & Production Builds

MARKET INTRODUCTIONLaunch Ver. 1.0

Mayo Manuscript

IEEE Manuscript

AF SYMPOSIUM HRS Meeting AF SYMPOSIUM HRS Meeting

Submit Abstracts

510 (k) Clearance

Market Launch Preparation


EP Sector M&A Activity

15

CompanyProof ofConcept Prototype

Clinical Data CE Mark FDA Sales

Acquirer/Investor Valuation

nContactFormed 2005 • • • • Atricure $149 million

Oct 2015CardioInsightFormed 2006 • • • • • • Medtronic $272 million

June 2015Topera MedicalFormed 2010 • • • • • Abbott $350 million

Dec 2014Bard EPDivision of CR Bard • • • • • • Boston Scientific $275 million

Nov 2013Rhythmia MedicalFormed 2004 • • • Boston Scientific $410 million

Oct 2012Ablation FrontiersFormed 2004 • • • • Medtronic $465 million

Feb 2009EP MedsystemsFormed 1993 • • • • • St. Jude $92.1 million

July 2008CryocathFormed 1995 • • • • • Medtronic $380 million

Nov 2008Endocardial SolutionsFormed 1992 • • • St. Jude $272 million

Jan 2005Prucka EngineeringFormed 1988 • • • • • GE Undisclosed

Nov 1999

Each acquired company was sold for an average of $296 million and a mean of $275 million. BioSig which has a better technology and is further in development then many of the acquired companies is currently undervalued at ~18 million.


Catalysts for Shareholder Value

16

PRE-CLINICAL DATA Mayo Clinic

Peer Review Cardiology JournalQ2 2016 Engineering Journal

Feb 2016 Heart Rhythm Society

May 2016 UCLA

2H 2016

UPLIST TO NASDAQ Q2 2016 Sell Side Research/Conferences

BUSINESS DEVELOPMENT Technology Partnerships International Distribution

FDA 510(k) CLEARANCE Q4 2016/Q1 2017


BioSig Investment Highlights

Large & Growing Cardiac Arrhythmia Patient Population ⇒Ablations Increasing 10%+ Annually

$4B Total Addressable Market for EP Devices at a 12.1% CAGR ⇒High Demand for New Technologies

World-Class Management Team, Board of Directors & Scientific Advisory Board

Aggressive M&A Activity ⇒ High Growth Sector

17


Contact BioSig

18

This document is being provided on a confidential basis by BioSig Technologies, Inc. solely for the information of those persons to whom it is transmitted. No person in any jurisdiction may treat this document as constituting either an offer to sell or solicitation of anoffer to buy any securities in the Company. A prospective subscriber must rely solely on the terms of and disclosure of information including important information regarding risks and conflicts of interest contained in the Company's final offering memorandum andrelated documents, the only basis on which subscriptions may be made.

Ken LondonerFounder, Executive Chairman

(203) 644-5200 [email protected]

Gregory CashPresident & Chief Executive Officer

(612) [email protected]

Brian McLaughlinVP, Corporate Finance & Investor Relations

(917) 370-9817 [email protected]


Deficiencies In Present Ablation

19

First Line Therapy for First Stages of AF:

Pulmonary Vein Isolation (PVI) -

Areas around Pulmonary Veins are ablated (blocked from firing inappropriate impulses)

ISSUES: PV reconnects Inability to detect gaps in ablation lines Late stage AF needs more than PVI

VENTRICULAR TACHYCARDIA (VT)

Scars are Main Ablation Targets

Viable myocardium within scar is responsible for arrhythmia

ISSUE: Identification of ablation targets within

the scar is difficult due to low signal levels and presence of noise


BioSig Technologies, Inc. (BSGM)

20

OTCQB: BSGMWWW.BIOSIGTECH.COM

KEY COMPANY DATA (03/07/16)

Recent price: $1.30

52-week range: $0.90 - $4.80

Primary shares i/o: 17.02 million

Market cap: $22.1 million

Headquarters: Minneapolis, MN

pure ep™ system...sources: 1. electrophysiology devices market - global industry analysis, size,...

Documents